MX338036B - Expresion proteinica a partir de acidos nucleicos multiples. - Google Patents

Expresion proteinica a partir de acidos nucleicos multiples.

Info

Publication number
MX338036B
MX338036B MX2013003820A MX2013003820A MX338036B MX 338036 B MX338036 B MX 338036B MX 2013003820 A MX2013003820 A MX 2013003820A MX 2013003820 A MX2013003820 A MX 2013003820A MX 338036 B MX338036 B MX 338036B
Authority
MX
Mexico
Prior art keywords
cho cell
selection agent
nucleic acid
eukaryotic selection
transfecting
Prior art date
Application number
MX2013003820A
Other languages
English (en)
Inventor
Erhard Kopetzki
Anne Stern
Hendrik Knoetgen
Ulrich Goepfert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338036(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX338036B publication Critical patent/MX338036B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método para la producción recombinante de una inmunoglobulina heteróloga secretada en una célula CHO que comprende las siguientes etapas: i) proporcionar una célula CHO la cual está adaptada para crecer en cultivo en suspensión, adaptada para crecer en medio libre de suero, libre de micoplasmas y libre de virus, ii) proporcionar un vector que comprende un origen de replicación procariótico, un primer ácido nucleico que confiere resistencia contra un agente de selección procariótico, un segundo ácido nucleico que codifica para la cadena pesada de la inmunoglobulina heteróloga, un tercer ácido nucleico que codifica para la cadena ligera de la inmunoglobulina heteróloga, un cuarto ácido nucleico que confiere resistencia contra un agente de selección eucariótico, iii) transfectar la célula CHO, en donde la transfección comprende a) transfectar la célula CHO con el vector que comprende un cuarto ácido nucleico que confiere resistencia contra un primer agente de selección eucariótico, b) seleccionar una célula CHO por crecimiento en medio de cultivo que contiene el primer agente de selección eucariótico, c) transfectar la célula CHO seleccionada con el vector que comprende un cuarto ácido nucleico que confiere resistencia contra un segundo agente de selección eucariótico diferente del primer agente de selección eucariótico, d) seleccionar una célula CHO mediante crecimiento selectivo en medio de cultivo que contiene el primero y segundo agentes de selección eucarióticos, iv) cultivar la célula CHO transfectada en un medio en presencia del primero y segundo agentes de selección eucarióticos bajo condiciones adecuadas para la expresión del segundo y tercer ácidos nucleicos, y v) recuperar la inmunoglobulina heteróloga secretada del medio de cultivo.
MX2013003820A 2007-10-12 2008-10-09 Expresion proteinica a partir de acidos nucleicos multiples. MX338036B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07019999 2007-10-12
PCT/EP2008/008523 WO2009046978A1 (en) 2007-10-12 2008-10-09 Protein expression from multiple nucleic acids

Publications (1)

Publication Number Publication Date
MX338036B true MX338036B (es) 2016-03-31

Family

ID=39204855

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2010003622A MX2010003622A (es) 2007-10-12 2008-10-09 Expresion proteinica a partir de acidos nucleicos multiples.
MX2013003820A MX338036B (es) 2007-10-12 2008-10-09 Expresion proteinica a partir de acidos nucleicos multiples.
MX2010003620A MX2010003620A (es) 2007-10-12 2008-10-13 Linea de celulas cho-k1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010003622A MX2010003622A (es) 2007-10-12 2008-10-09 Expresion proteinica a partir de acidos nucleicos multiples.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010003620A MX2010003620A (es) 2007-10-12 2008-10-13 Linea de celulas cho-k1.

Country Status (20)

Country Link
US (5) US8771988B2 (es)
EP (4) EP2592148B1 (es)
JP (2) JP5642549B2 (es)
KR (2) KR101280704B1 (es)
CN (2) CN101815786A (es)
AU (2) AU2008309934B2 (es)
BR (2) BRPI0818165B8 (es)
CA (2) CA2701646C (es)
DK (1) DK2592148T3 (es)
ES (1) ES2695999T3 (es)
HR (1) HRP20181833T1 (es)
HU (1) HUE039950T2 (es)
IL (2) IL203902A0 (es)
LT (1) LT2592148T (es)
MX (3) MX2010003622A (es)
PL (1) PL2592148T3 (es)
PT (1) PT2592148T (es)
SI (1) SI2592148T1 (es)
TR (1) TR201816045T4 (es)
WO (2) WO2009046978A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2441831B9 (en) * 2009-06-11 2019-03-06 Inter-University Research Institute Corporation Research Organization of Information and Systems Process for production of protein
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
EP2524041A4 (en) * 2009-11-16 2013-08-07 Acyte Biotech Pty Ltd RECOMBINANT ANTIBODY VECTOR
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
BR112012027434B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Processo para produção de um polipeptídeo recombinante compreendendo uma fase de produção
US9068198B2 (en) 2010-09-15 2015-06-30 Medimmune Limited Chinese hamster ovary cell line
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
HRP20200744T1 (hr) 2011-12-22 2020-07-24 F. Hoffmann - La Roche Ag Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2674495A1 (en) * 2012-06-14 2013-12-18 Sanofi CHO expression system
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014145098A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EP4570318A3 (en) 2013-11-27 2025-10-15 Zymeworks BC Inc. Bispecific antigen-binding constructs targeting her2
WO2015148515A1 (en) * 2014-03-24 2015-10-01 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
HRP20231139T1 (hr) 2014-05-06 2024-01-05 F. Hoffmann - La Roche Ag Proizvodnja heteromultimernih proteina upotrebom stanica sisavaca
SG11201700023WA (en) * 2014-07-16 2017-02-27 Heartseed Inc New undifferentiated stem cell removal and myocardial purification and refinement culture medium
EP3289092B1 (en) * 2015-04-27 2020-02-12 Momenta Pharmaceuticals, Inc. Method of manufacturing a therapeutic protein
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
CA3020839A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
GB201718088D0 (en) * 2017-11-01 2017-12-13 Autolus Ltd Vectors
CN111019881B (zh) * 2019-11-21 2020-10-09 中山康天晟合生物技术有限公司 一种适应高渗透压、高铵离子、高乳酸生长环境的细胞
EP4400515A3 (en) 2020-04-24 2024-10-23 F. Hoffmann-La Roche AG Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN112920995A (zh) * 2021-03-31 2021-06-08 赵峻岭 一种间充质干细胞培养血清加油包及其应用
CN115521919B (zh) * 2022-11-04 2023-04-11 广州誉衡生物科技有限公司 一种调节pd-1抗体和lag-3抗体酸性电荷异构体的cho细胞培养方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912038A (en) 1984-12-11 1990-03-27 California Biotechnology Inc. Recombinant DNA sequence encoding alveolar surfactant protein
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
EP0368926A4 (en) 1987-07-16 1991-11-27 Codon Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
EP0319206A3 (en) 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
WO1989010959A1 (en) * 1988-05-06 1989-11-16 Codon Supertransformants for high expression rates in eukaryotic cells
DD287531A5 (de) 1988-06-16 1991-02-28 Akademie Der Wissenschaften,De Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
JP2859679B2 (ja) * 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
EP0569678A3 (de) 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
FI955261A7 (fi) 1993-05-04 1996-01-03 Cytel Corp P-selektiinin vasta-aineita ja niiden käyttö
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995017513A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Retransformation of filamentous fungi
US5719050A (en) 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5726041A (en) 1995-08-30 1998-03-10 Gentest Corporation Method for detecting a receptor-ligand complex using a cytochrome P450 reporter gene
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
WO1999026463A2 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
EP1066371A1 (en) 1998-03-18 2001-01-10 Pharmacopeia, Inc. Eukaryotic cells stably expressing genes from multiple transfected episomes
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
TW570977B (en) 1998-12-07 2004-01-11 Li-Wei Hsu An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
DE19920712A1 (de) 1999-05-05 2000-11-09 Rhein Biotech Proz & Prod Gmbh Verfahren zum Herstellen eines rekombinanten Proteines
US6413744B1 (en) * 1999-08-25 2002-07-02 Immunex Corporation Methods and host cells for improved cell culture
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
DE10036491A1 (de) * 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
PL370550A1 (en) 2001-11-28 2005-05-30 Sandoz Ag Method for producing a recombinant polypeptide
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
AU2003213791A1 (en) 2002-03-05 2003-09-22 Vitra Bioscience, Inc. Multiplexed cell transfection using coded carriers
DE10213201A1 (de) 2002-03-25 2003-10-16 Roche Diagnostics Gmbh Erzeugung von schwach aktiven oder inaktiven Mutanten von Alkalischer Phosphatase und deren Expression in Hefe
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
TW200902555A (en) * 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
WO2007109052A2 (en) * 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using cd4 antibodies
DK2177536T3 (da) * 2006-03-30 2014-07-14 Glaxo Group Ltd Antistoffer mod amyloid-beta-peptid
US20090022720A1 (en) 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides

Also Published As

Publication number Publication date
HRP20181833T1 (hr) 2019-01-11
KR20100059967A (ko) 2010-06-04
LT2592148T (lt) 2018-12-10
PT2592148T (pt) 2018-11-12
WO2009046978A1 (en) 2009-04-16
JP2011500009A (ja) 2011-01-06
EP2592147A1 (en) 2013-05-15
EP2592148A1 (en) 2013-05-15
BRPI0818165A2 (pt) 2014-10-14
IL203900A (en) 2014-08-31
MX2010003620A (es) 2010-04-14
JP2010540583A (ja) 2010-12-24
KR20100059969A (ko) 2010-06-04
CA2701646A1 (en) 2009-04-16
US9428766B2 (en) 2016-08-30
AU2008309934A1 (en) 2009-04-16
US20140335609A1 (en) 2014-11-13
US20100221781A1 (en) 2010-09-02
JP5642549B2 (ja) 2014-12-17
BRPI0818165B8 (pt) 2021-05-25
CA2701677A1 (en) 2009-04-16
IL203902A0 (en) 2011-07-31
US20100249379A1 (en) 2010-09-30
US20170166923A1 (en) 2017-06-15
US20190233842A1 (en) 2019-08-01
CA2701646C (en) 2019-02-26
SI2592148T1 (sl) 2018-12-31
BRPI0818165B1 (pt) 2020-10-27
CN101815786A (zh) 2010-08-25
CN101821394A (zh) 2010-09-01
IL203900A0 (en) 2011-07-31
EP2207882A1 (en) 2010-07-21
PL2592148T3 (pl) 2019-01-31
HUE039950T2 (hu) 2019-02-28
EP2592148B1 (en) 2018-09-12
WO2009047007A1 (en) 2009-04-16
TR201816045T4 (tr) 2018-11-21
BRPI0818536A2 (pt) 2014-10-14
MX2010003622A (es) 2010-04-14
EP2207881A1 (en) 2010-07-21
US8771988B2 (en) 2014-07-08
KR101280704B1 (ko) 2013-07-01
ES2695999T3 (es) 2019-01-11
DK2592148T3 (en) 2018-12-10
AU2008309881A1 (en) 2009-04-16
AU2008309934B2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
MX2010003622A (es) Expresion proteinica a partir de acidos nucleicos multiples.
Rasala et al. The microalga Chlamydomonas reinhardtii as a platform for the production of human protein therapeutics
KR101812348B1 (ko) 단백질의 생산 방법
AR110864A2 (es) Procesos para cultivos celulares
CN101687910B (zh) 具有高效分泌信号序列的哺乳动物表达载体
JP2016518833A5 (es)
NZ608972A (en) Engineered nucleic acids and methods of use thereof
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
HRP20130921T1 (hr) Staniäśni klon koji proizvodi fsh
US12577293B2 (en) Method for the expression of polypeptides using modified nucleic acids
CN104450785A (zh) 使用编码靶向核酸内切酶附着体载体的基因组编辑方法及试剂盒
CN106987559A (zh) 一种重组chok1细胞株的构建方法及其应用
ATE454444T1 (de) Verfahren zur herstellung rekombinanter proteine
FI2875047T3 (fi) Tuotantosolulinjan tehostajat
CN102498212A (zh) Cho/cert细胞系
CN107034234B (zh) 一种用于敲除cho细胞中fut8和dhfr两种基因的试剂盒
DE602004023408D1 (de) Agments unter verwendung einer e.coli-signalsequenz sowie verfahren zur massenproduktion des antikörperfragments
Suarez-Patino et al. Transient expression of rabies virus glycoprotein (RVGP) in Drosophila melanogaster Schneider 2 (S2) cells
US10590426B2 (en) Genetic control of cell size
CN103361342B (zh) 一种转基因定位整合的方法及其应用
CN105622729B (zh) 一种靶向编辑gs基因的多肽及其蛋白
WO2007015691A3 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
CN103339255A (zh) 蛋白质的生产方法
CN107012146B (zh) 基于位点特异性重组的四膜虫表达载体及其构建和应用
CN109153985A (zh) 转化体、以及转铁蛋白的制造方法